2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 296

Prevalence of Elbow Arthritis in Patients with Rheumatoid Arthritis: A Prospective Ultrasound Study

Imaging Of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 410

Prevalence of Malignancy in Myositis Patients with Anti-aminoacyl-tRNA Synthetase Antibodies: A Single Center Retrospective Study and Literature Review

Muscle Biology, Myositis & Myopathies Poster I

9:00AM-11:00AM: Abstract Number: 608

Prevalence of Radiographic Entheseal Lesions at the Hip and Pelvic Region in Patients with Ankylosing Spondylitis versus Controls

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 181

Prevalence of Renal Impairment in a US Rheumatoid Arthritis Population

Epidemiology & Public Health Poster I: RA

9:00AM-11:00AM: Abstract Number: 352

Primary Hyperparathyroidism Is Associated with a Higher Level of Serum Uric Acid: A Systematic Review and Meta-analysis

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 454

Principal Component Analysis Identifies Unique Sub-Populations in Rheumatoid Arthritis Using a Combination of Serological Biomarkers: A Cross Sectional Study

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 703

Prior Knowledge Feature Reduction Improves Performance in a Machine Learning Model of Systemic Lupus Erythematosus Flare Status Using Serum Proteomics

SLE – Clinical Poster I: Epidemiology & Pathogenesis

9:00AM-11:00AM: Abstract Number: 481

Production of IL17A in Synovial Tissue Correlates with MRI RAMRIS Scores in ACPA Positive Early Rheumatoid Arthritis

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 465

Prognostic Factors and Clinical Outcome Modifiers in Patients with Rheumatoid Arthritis: A Review

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

9:00AM-11:00AM: Abstract Number: 373

Prognostic Factors and Long-term Outcomes in Cardiac Sarcoidosis

Miscellaneous Rheumatic & Inflammatory Disease Poster I: Fibroinflammatory & Granulomatous Disorders & Therapies

9:00AM-11:00AM: Abstract Number: 300

Proliferative Globular Synovitis, an Ultrasound Pattern Associated with Seropositive Rheumatoid Arthritis

Imaging Of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 596

Prostaglandin Receptor EP4 Drives Pathogenic Th17 Cell Development in Ankylosing Spondylitis and Is a New Marker of Disease Activity

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 431

Psychometric Properties of the Pediatric Patient-Reported Outcomes Measurement Information System (PROMIS®) Item Banks in a Dutch Clinical Sample of Children with Juvenile Idiopathic Arthritis

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 308

Quality Control of Antinuclear Antibody Detection by Indirect Immunofluorescence and Flow Cytometry-based Recombinant Antigen Assays

Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

9:00AM-11:00AM: Abstract Number: 473

RA Presents in Disease Patterns Impacting Treatment Response

RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].